PAREXEL?S TECHNOLOGY DIVISION APPOINTS MUSCULOSKELETAL EXPERT DR. SARAH WARNER TO ITS MEDICAL IMAGING GROUP
BOSTON, MA, October 18, 2006 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that musculoskeletal expert Dr. Sarah Warner has joined the Perceptive Informatics Medical Imaging Services Group as Associate Medical Director.
“Our clients depend on Perceptive’s therapeutic area expertise, clinical knowledge and advanced medical imaging techniques to help detect evidence of efficacy while improving the speed and efficiency of their clinical development programs,” said Todd Joron, Corporate Vice President and General Manager of PAREXEL’s Perceptive Informatics Division. “The musculoskeletal/bone therapeutic area relies heavily on medical imaging to advance the research of new treatments. Dr. Warner’s appointment further strengthens our commitment to this area.”
Before joining PAREXEL, Dr. Warner held the position of Senior Research Fellow of Orthopedics and Sports Medicine at the University of Washington, and was formerly a Research Fellow at the University of Utah Graduate School. Dr. Warner has conducted dual energy x-ray absorptiometry (DXA) acquisition, analysis and reporting for the National Institutes of Health and University of Connecticut Health Center. Dr. Warner holds a Ph.D. from the University of Utah, an M.A. from the University of Connecticut, and received her license and certifications in clinical densitometry and radiology. She has won several grants in women’s health and received a doctoral research fellowship from the National Aeronautics & Space Administration (NASA). Dr. Warner has authored numerous papers and given presentations addressing bone loss and density, osteoporosis, sports medicine and women’s health issues. She is a long-standing member of the American Society of Bone and Mineral Research.
Dr. Warner joins Perceptive’s team of therapeutic and medical imaging experts that provides sponsors with a range of capabilities in the application of imaging techniques, used from early development through peri-approval studies. Perceptive Informatics Medical Imaging Services Group has expertise in multiple therapeutic areas, as well as significant experience in the use of novel modalities such as FDG-PET (fluorodeoxyglucose-positron emission tomography) and DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging).
About Perceptive Informatics, PAREXEL’s Technology Division
PAREXEL’s Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT™ solution is Perceptive’s market-leading CTMS product with 25,000 users worldwide, and Perceptive’s INITIATOR™ trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit www.perceptive.com.
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 51 locations throughout 40 countries around the world, and has approximately 5,600 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the amendment or interpretation of Financial Accounting Standards Board Statement No. 123 (revised 2004), Share-Based Payment (“Statement 123R”), which could change the Company’s current assessment of the effects of the adoption of Statement 123R on the acceleration of equity grants, the assumptions inherent in equity pricing models under Statement 123R and the final results of the closing of the Company’s books for future financial periods; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-K for the period ended June 30, 2006 as filed with the SEC on September 8, 2006, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.